Answers are grounded in this paper and cite their sources.
Tubulointerstitial inflammation plays an important role in the development of diabetic kidney disease (DKD), and tubular epithelial cells (TECs) act as a driving force in the inflammatory cascade. Our previous study showed that myeloid-derived growth factor (MYDGF) can attenuate podocyte injury and proteinuria in DKD mice. However, the role and regulation of MYDGF for tubulointerstitial inflammation in DKD remain unclear. Here, we found that myeloid cell-specific MYDGF deficiency exacerbated renal dysfunction, tubulointerstitial inflammation, and TEC injury, whereas restoring myeloid cell-derived MYDGF through bone marrow transplantation or myeloid cell-specific overexpression mitigated these effects in vivo. Functionally, MYDGF attenuated the inflammatory response and apoptosis in TECs induced by high glucose and palmitic acid, as demonstrated in both in vitro and ex vivo experiments. Mechanistically, the renoprotection of MYDGF involved down-regulation of the inhibitory kappa B kinase beta/nuclear factor-kappa B (IKKβ/NF-κB) pathway. Bidirectional functional assays in human kidney-2 (HK-2) cells further supported a key mediating role for IKKβ/NF‑κB signaling in MYDGF-conferred tubular protection. Thus, our studies suggest that myeloid cell-derived MYDGF is associated with the alleviation of tubulointerstitial inflammation and TEC injury in DKD, and that it may participate in bone marrow–kidney crosstalk.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: